TG100-115

TG100-115 is an inhibitor of p110 PI3K and p110 PI3K that exhibits anti-inflammatory and anti-asthma activities. TG100-115 decreases pulmonary eosinophil levels and accumulation of IL-13 and mucin in animal models of asthma and chronic obstructive pulmonary disorder (COPD), decreasing inflammation. TH100-115 also inhibits edema and inflammation induced by VEGF and platelet activating factor (PAF) in other animal models, decreasing development of infarcts and improving cardiac function. As a result of its cardioprotective activity, TG100-115 is currently in clinical trials as a potential treatment to reduce acute myocardial infarctions.